Arno, With Potential Suitor in Opko, Goes After Endometrial Cancer

11/6/13Follow @benthefidler

What are Opko Health (NYSE: OPK) and the founding partner of private equity firm TPG Capital doing circling a seven-year-old biotech startup that isn’t even close to owning a marketed product? Apparently buying into the idea that that startup, Flemington, NJ-based Arno Therapeutics, may potentially be on to something.

This past week, Opko, its CEO Phillip Frost, and TPG Capital founding partner David Bonderman, teamed with a group of existing investors (among them affiliates of George Soros’ Soros Fund Management) to provide Arno—a small company whose stock trades over the counter—with a $30.7 million private placement of newly issued stock and warrants. As part of the financing, Opko was given the first crack at a potential strategic deal with Arno in the form of an exclusive 45-day negotiating window on a buyout, partnership, or licensing pact, should Arno decide to pursue one. Opko was also given a board observer seat.

“It’s definitely a good endorsement of what we’re doing here,” says Arno CEO Glenn Mattes.

The big-name group is clearly willing to bet on Arno’s plan for a well-studied drug candidate called onapristone, which is what’s known as an anti-progestin, a synthetic compound that suppresses the actions of the hormone progesterone.

Onapristone was initially kicked around two decades ago by Schering AG (now part of Germany-based Bayer) as a treatment for endometriosis, uterine leiomyomas (benign tumors in the uterus), and possibly as a contraceptive or a breast cancer treatment. Mattes says that Schering ran a Phase 2 cancer study on the drug in an “unselected patient population,” and while researchers found that onapristone could demonstrated an ability to shrink tumors, investigators discovered certain patients in the trial had elevated levels of liver enzymes.

“[This was] an unacceptable safety profile for benign gynecological conditions, but [it] can be acceptable and manageable in the oncology indications,” he says.

Even so, Schering discontinued development of the drug, and it eventually ended up in the hands of Bridgewater, NJ-based Invivis Pharmaceuticals, which was looking for a partner to help move it forward. Arno grabbed worldwide rights to it through a February 2012 licensing deal, paying $500,000 up front and tying $15.1 million in potential milestones to the transaction. Arno is now working with Invivis through a research collaboration to develop the drug.

“We looked at the whole concept of anti-progestins in the treatment of cancer and realized that [there] will be an emerging interest,” Mattes says of scouting the drug, noting that there are no currently approved anti-progestins for cancer.

It was timely for Arno. The company had just decided to abandon its rights to an experimental cancer drug it had licensed from the University of Pittsburgh. And though it has two other programs in its portfolio, it saw a quicker, clearer path to market with onapristone.

Arno’s resulting idea: pair onapristone with a companion diagnostic that highlights … Next Page »

Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at bfidler@xconomy.com Follow @benthefidler

Single Page Currently on Page: 1 2

By posting a comment, you agree to our terms and conditions.